The trademark application IMZAF was filed by Novartis AG, a corporation established under the laws of the Swiss Confederation (the "Applicant"). The application was published for oppositions on July 25, 2024, and it was registered by office on November 1, 2024 without any oppositions.
The application was filed in English (French was selected as the second language).